피부암 환자를 위한 방사선 요법 및 세미플리맙 연구
방사선 요법 및 CeMiPlimAb의 II상, 다기관, 단일 팔 임상 시험: 국부적으로 진행된 절제 불가능한 피부 편평 세포 암종에 대한 Rwlc 면역 요법: RAMPART
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- University of Colorado (Data Collection Only)
-
-
Florida
-
Tampa, Florida, 미국, 33612
- Moffitt Cancer Center (Data Collection Only)
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities)
-
Middletown, New Jersey, 미국, 07748
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Montvale, New Jersey, 미국, 07645
- Memorial Sloan Kettering Bergen (All protocol activities)
-
-
New York
-
Commack, New York, 미국, 11725
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)
-
Harrison, New York, 미국, 10604
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)
-
Rockville Centre, New York, 미국, 11553
- Memorial Sloan Kettering Nassau (All protocol activities)
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic (Data Collection Only)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19111
- Fox Chase Cancer Center (Data Collection Only)
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Medical University of South Carolina
-
-
Washington
-
Seattle, Washington, 미국, 98109
- University of Washington (Data Collection Only)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Biopsy proven cutaneous squamous cell carcinoma which is locally advanced
- Mixed histology tumors that are predominantly squamous cell carcinoma are eligible
- Locally advanced primary tumor is T3-T4 and/or N+ by AJCC and/or UICC 8th edition clinical criteria
-
T3-T4 primary tumor characteristics noted below:
- Non-eyelid tumor >4 cm in maximum dimension or with bone erosion or invasion, perineural invasion of nerve 0.1 mm or larger, or invasion beyond subcutaneous fat or >6 mm from granular layer of adjacent normal epidermis
- Eyelid tumor >2 cm or invading adjacent ocular, orbital or facial structures
-
≥18 years old
-
Unresectable or medically inoperable according to local multidisciplinary consensus for reasons such as:
- Tumor or regional lymph node metastases that has recurred despite ≥2 prior surgical procedures, with another curative resection unlikely
- Tumor or nodal disease with significant local invasion that precludes complete resection
- Tumor or nodal disease in anatomically challenging area where surgery may result in significant disfigurement or dysfunction (amputation of nose, ear, eye, digit, limb, etc)
- Medical contraindication to surgery
- Patient refusal of surgery due to anticipate morbidity
-
ECOG ≤2
-
Adequate bone marrow and metabolic function (by blood tests)
- Total bilirubin ≤1.5 x upper limit of normal
- Aspirate aminotransferase (AST) ≤3 x upper limit of normal
- Alanine aminotransferase (ALT) ≤3 x upper limit of normal
- Alkaline phosphatase ≤2.5 x upper limit of normal
- Serum creatinine ≤1.5 x upper limit of normal or estimated creatinine clearance >30 mL/min according to Cockcroft-Gault formula
- Hemoglobin >9 g/dL
- Absolute neutrophil count ≥1.5 x10^9/L
- Platelet count ≥75 x10^9/L
-
Able to provide informed consent
-
Acceptable candidate for curative intent radiotherapy and Cemiplimab immunotherapy, in opinion of radiation and medical oncologist, respectively
-
Life expectancy >18 months
Exclusion Criteria:
-
Primary tumor originating on the mucosal (non-hair bearing) lip or nose, anogenital (penis, scrotum, vulva, perianal) area
-
Iatrogenic immunosuppression (>prednisone 10 mg/day or equivalent within 14 days of initiation of treatment)
-
Women of child bearing potential unwilling or unable to use effective contraception while receiving treatment with cemiplimab and for 4 months thereafter
-
Distant metastases
-
Clinically significant autoimmune disease that requires iatrogenic immunosuppression
o For example, severe rheumatoid arthritis requiring disease modifying antirheumatic drugs, such as methotrexate
-
Current or previous hematopoietic malignancy (leukemia, lymphoma)
-
Prior allogeneic transplant of solid organ or bone marrow
-
Concurrent malignancies with >10% risk of metastasis or death within 2 years
-
Prior aPD1 immunotherapy or PI3Kδ inhibitor use
-
Prior radiotherapy for the cutaneous squamous cell carcinoma requiring treatment
-
Other ongoing cancer therapy
o Adjuvant endocrine therapy is permitted for patients with prostate or breast cancer
-
Uncontrolled HIV or infectious hepatitis (viral load detectable in patient with known infection)
-
Pregnancy or breastfeeding
-
Comorbid or diagnostic abnormalities within the last year that would interfere with interpretation of study results
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Participants with locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC
Participants have locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC |
Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab. Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event Free Survival
기간: 18 months
|
The primary endpoint for this study is event free survival at 18 months (week 78 +/- 3 weeks) after starting cemiplimab. |
18 months
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Christopher Barker, MD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 22-090
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .